argenx SE
ARGX
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathyā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$700.45
Price-1.19%
-$8.40
1Y
Price
Market Cap
$43.346b
Large
Price/Earnings 3y Avg5y Avg
35.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+32.8%
EBITDA Margin+36.4%
Net Profit Margin+16.9%
Free Cash Flow Margin+32.8%
EBITDA Margin+36.4%
Net Profit Margin+16.9%
Free Cash Flow MarginRevenue
$4.164b
+150.7%
1y CAGR+142.6%
3y CAGR+102.6%
5y CAGREarnings
$1.296b
+158.7%
1y CAGR+199.8%
3y CAGR+131.4%
5y CAGREPS
$19.63
+168.9%
1y CAGR+192.4%
3y CAGR+128.4%
5y CAGRBook Value
$7.323b
$8.683b
Assets$1.360b
Liabilities$83.487m
DebtDebt to Assets
1.0%
0.1x
Debt to EBITDAFree Cash Flow
$844.301m
+599.8%
1y CAGR+239.8%
3y CAGR+171.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company